Research and Development Investment: Bio-Techne Corporation vs Bausch Health Companies Inc.

A Decade of R&D Investment: Bio-Techne vs. Bausch Health

In the ever-evolving landscape of biotechnology and pharmaceuticals, research and development (R&D) investments are pivotal. Over the past decade, Bio-Techne Corporation and Bausch Health Companies Inc. have demonstrated contrasting strategies in their R&D expenditures.

From 2014 to 2023, Bausch Health's R&D spending surged by approximately 145%, peaking in 2023. This reflects their aggressive pursuit of innovation and market leadership. In contrast, Bio-Techne's R&D investment grew by about 200% over the same period, showcasing their commitment to expanding their technological capabilities.

Interestingly, while Bausch Health consistently outspent Bio-Techne, the latter's growth rate in R&D investment was notably higher. This suggests a strategic focus on scaling their research capabilities. However, data for 2024 is missing for Bausch Health, leaving a gap in the comparative analysis. As these companies continue to innovate, their R&D investments will likely shape the future of the industry.